San Mateo, CA – According to filings with the U.S. Securities and Exchange Commission, Bluejay Therapeutics is raising $41,150,200.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Keting Chu played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Bluejay Therapeutics
The mission of Bluejay Therapeutics is to develop innovative cures for infectious diseases with the first target indication of chronic HBV infection. Bluejay has exclusively licensed global rights to advance several HBV programs, including a best-in-class anti-HBsAg monoclonal antibody.

To learn more about Bluejay Therapeutics, visit http://www.bluejaytx.com/

Contact:
Keting Chu, Chief Executive Officer
650-218-5487
keting@bluejaytx.com
https://www.linkedin.com/in/keting-chu-5a37151/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved